Burzynski Research
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting se… Read more
Burzynski Research (BZYR) - Total Liabilities
Latest total liabilities as of November 2025: $69.61K USD
Based on the latest financial reports, Burzynski Research (BZYR) has total liabilities worth $69.61K USD as of November 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Burzynski Research - Total Liabilities Trend (1998–2025)
This chart illustrates how Burzynski Research's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Burzynski Research Competitors by Total Liabilities
The table below lists competitors of Burzynski Research ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Riedel Resources Ltd
AU:RIE
|
Australia | AU$1.01 Million |
|
Nova Net Lease REIT
PINK:NNLRF
|
USA | $3.40 Million |
|
Ortin Laboratories Limited
NSE:ORTINLAB
|
India | ₹38.40 Million |
|
AIS Resources Ltd
V:AIS
|
Canada | CA$2.33 Million |
|
Sultan Resources Ltd
AU:SLZ
|
Australia | AU$389.52K |
|
Mace Security Intl
PINK:MACE
|
USA | $4.42 Million |
|
Artea SA
PA:ARTE
|
France | €236.12 Million |
|
MATERION
MU:BEM
|
Germany | €925.12 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down Burzynski Research's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 30.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Burzynski Research's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Burzynski Research (1998–2025)
The table below shows the annual total liabilities of Burzynski Research from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-02-28 | $42.48K | +54.86% |
| 2024-02-29 | $27.43K | +75.17% |
| 2023-02-28 | $15.66K | +353.29% |
| 2022-02-28 | $3.46K | -92.62% |
| 2021-02-28 | $46.80K | -72.86% |
| 2020-02-29 | $172.44K | -17.42% |
| 2019-02-28 | $208.82K | +52.84% |
| 2018-02-28 | $136.63K | +212.42% |
| 2017-02-28 | $43.73K | -58.35% |
| 2016-02-29 | $105.00K | -26.05% |
| 2015-02-28 | $141.99K | -7.14% |
| 2014-02-28 | $152.90K | +72.60% |
| 2013-02-28 | $88.59K | +42.97% |
| 2012-02-29 | $61.96K | -14.94% |
| 2011-02-28 | $72.85K | +1.95% |
| 2010-02-28 | $71.46K | -31.16% |
| 2009-02-28 | $103.81K | +51.41% |
| 2008-02-29 | $68.56K | +3.71% |
| 2007-02-28 | $66.10K | +33.01% |
| 2006-02-28 | $49.70K | -42.64% |
| 2005-02-28 | $86.64K | -18.82% |
| 2004-02-29 | $106.74K | +51.50% |
| 2003-02-28 | $70.45K | +21.81% |
| 2002-02-28 | $57.84K | -32.01% |
| 2001-02-28 | $85.07K | -59.30% |
| 2000-02-29 | $209.02K | -38.42% |
| 1999-02-28 | $339.40K | -59.37% |
| 1998-02-28 | $835.39K | -- |